Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk.

Pharmacogenomics - 1 Jan 2022

Kononov Stanislav, Mal Galina, Azarova Iuliia, Klyosova Elena, Bykanova Marina, Churnosov Mikhail, Polonikov Alexey

Abstract excerpt

Aim: Polymorphisms at LPA, LDLR, APOE, APOC1, MYLIP and ABCG2 are attractive targets for assessment of their impact on lipid-lowering therapy with rosuvastatin. The present study investigated whether polymorphisms at these genes are associated with the risk of coronary artery disease (CAD) development, and reduction of atherogenic lipids and carotid intima-media thickness (CIMT) in CAD patients, taking...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoprotein C-I
Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carotid Intima-Media Thickness

Share to Coronary Artery Disease

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Lipids

Share to Receptors, LDL

Share to Rosuvastatin Calcium

Source

Identifiers

PMID: 34905955
DOI: 10.2217/pgs-2021-0097

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk.PMID 34905955Read ↗

Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.Semantic proximity Read ↗

Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy.Semantic proximity Read ↗

Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate.Semantic proximity Read ↗

Genome-wide association of lipid-lowering response to statins in combined study populations.Semantic proximity Read ↗

Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes.Semantic proximity Read ↗

Pharmacogenetic determinants of statin-induced reductions in C-reactive protein.Semantic proximity Read ↗

Twenty-Five Novel Loci for Carotid Intima-Media Thickness: A Genome-Wide Association Study in >45 000 Individuals and Meta-Analysis of >100 000 Individuals.Semantic proximity Read ↗

LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins.Semantic proximity Read ↗

Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients.Semantic proximity Read ↗

Pharmacogenomics of Rosuvastatin: A Glocal (Global+Local) African Perspective and Expert Review on a Statin Drug.Semantic proximity Read ↗

Risk scores of common genetic variants for lipid levels influence atherosclerosis and incident coronary heart disease.Semantic proximity Read ↗

Meta-analysis of genome-wide association studies of HDL cholesterol response to statins.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.